Teva board OKs $3B buyback plan; Merck to pay $24M in Medicaid suit;

@FiercePharma: EU reins in exports of lethal-injection drugs, barring sale in countries still using death penalty. News | Follow @FiercePharma

> Teva Pharmaceutical Industries ($TEVA) says its board approved a $3 billion share buyback plan, or about 7.5% of its outstanding shares. News

> Merck ($MRK) has agreed to pay Massachusetts $24 million to settle a Medicaid fraud lawsuit. Story

> India's Zydus Cadila bought Mumbai-based antibiotics maker Biochem in a bid to grow its business in finished drugs. Item

> Akzo Novel was cited by FDA for failures at its active pharmaceutical ingredient plant in Los Reyes La Paz, Mexico. Article

> Marsh Supermarkets won a $19.5 million judgment against Roche over a sublease deal gone bad. Story

> The ringleader of a Houston-based smuggling operation was ordered to pay $140,000 in restitution to Eli Lilly ($LLY) and Pfizer ($PFE) for selling counterfeit versions of ED drugs. Report

Biotech News

@FierceBiotech: Tiny robots may be next big drug-delivery thing. News | Follow @FierceBiotech

@JohnCFierce: A struggling AstraZeneca commits $140M to cancer pact as it inks back-to-back deals. Story | Follow @JohnCFierce

@RyanMFierce: Takeda doesn't say how many jobs will be impacted in the move to consolidate in San Diego. Release | Follow @RyanMFierce

@MarkHFierce: Perosphere debuts! It has connections with Brown, Harvard and MIT, among others. Article | Follow @MarkHFierce

> AZ commits $140M to cancer pact as it inks back-to-back deals. News

> Takeda picks up a pair of cancer drugs in $310M Intellikine buyout. More

Medical Device News

> Philips, Steris to add 200 jobs in Ohio. Article

> Report: GE plans to add 200 engineers in China. Story

Drug Delivery News

> Pfizer to employ Antares drug-delivery tech for mystery product. News

> Perosphere launches with Brown, Harvard and MIT connections. Article

> Say it with lollipops to treat oral thrush. Item

> Eli Lilly advances drug delivery tech deals with Starpharma, Arecor. Story

Biomarkers News

> Biomarker predicts tamoxifen breast cancer response. More

> Urinary serotonin may be key to test for depression. Story

And Finally... Medieval knights may have suffered from PTSD, researcher says. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.